Information Library
Case Studies - Cardiovascular
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Successful Launch of Cardiovascular Risk Assessment Program
November 18, 2009
Read how Innovex is working with the UK National Health Service to assess large numbers of people at risk for cardiovascular disease. -
Takeda Hits the Ground Running in New European Territory, with Help from Innovex
September 25, 2009
Our customer was faced with the challenge to launch a countrywide sales team in Spain within 12 weeks. -
Cardiovascular management in the UK
September 23, 2009
This case study reviews how a Primary Care Trust used a combination of social marketing and Nurse Advisors to bring cardiovascular care to local communities. -
Multiple Phase I Study for Two Compounds
June 30, 2009
Learn how Quintiles efficiently managed 15 Phase I studies. -
QT Population Modeling and Simulation Case Study
June 15, 2009
The importance of determining the most strategic Phase I/IIa study conducted by leading specialists shouldn’t be understated. Gain insight into QT and Population Modeling & Simulation. -
Heart Failure
March 27, 2009
A double-blind, randomized, placebocontrolled trial evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction -
Cardiovascular Expertise Results in Faster Enrollment Speed
March 27, 2009
Mega-trials require mega-expertise, especially when the global study is for an innovative cardiovascular drug to treat patients with acute coronary syndrome who have also undergone coronary artery bypass surgery. -
Chronic Heart Failure
March 27, 2009
A phase II, double-blind, randomized, placebocontrolled, dose-comparative study of the efficacy, tolerability and safety of Drug X in subjects with chronic heart failure NYHA Class II/III
Page 1 of 1 (8 items)